Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial
- PMID: 30396557
- DOI: 10.1016/j.fertnstert.2018.07.003
Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial
Abstract
Objective: To assess the efficacy of an etonogestrel (ENG)-releasing contraceptive implant or the 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS) in the control of endometriosis-associated pelvic pain.
Design: Noninferiority randomized clinical trial in which women with endometriosis were assigned to use an ENG implant (experimental treatment) or an LNG-IUS (active comparator). Monthly follow-up visits were conducted up to 6 months.
Setting: University teaching hospital.
Patient(s): One hundred three women, with endometriosis-associated chronic pelvic pain, dysmenorrhea, or both for more than 6 months. In cases of deep endometriosis, vaginal ultrasonography and magnetic resonance imaging were used as additional diagnostic tools.
Intervention(s): The ENG implant or the LNG-IUS were inserted within the first 5 days of the menstrual cycle.
Main outcome measure(s): Daily scores of noncyclic pelvic pain and dysmenorrhea were evaluated using a daily visual analogue scale. Health-related quality of life was evaluated using the Endometriosis Health Profile-30 questionnaire at baseline and up to 6 months. Bleeding patterns were assessed daily from a menstrual calendar.
Result(s): Both contraceptives improved significantly the mean visual analogue scale endometriosis-associated pelvic pain and dysmenorrhea, without significant differences between treatment group profiles. Health-related quality of life improved significantly in all domains of the core and modular segments of the Endometriosis Health Profile-30 questionnaire, with no difference between both treatment groups. The most common bleeding patterns at 180 days of follow-up were amenorrhea and infrequent bleeding and infrequent bleeding and spotting among ENG implant and LNG-IUS users, respectively.
Conclusion(s): In this noninferiority study both contraceptives improved significantly pelvic pain, dysmenorrhea, and health-related quality of life in endometriosis.
Clinical trial registration number: Clinicaltrials.gov under number NCT02480647.
Keywords: Endometriosis; etonogestrel-releasing contraceptive implant; levonorgestrel-releasing intrauterine system; pelvic pain.
Copyright © 2018 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months.Eur J Contracept Reprod Health Care. 2020 Apr;25(2):133-140. doi: 10.1080/13625187.2020.1725461. Epub 2020 Feb 18. Eur J Contracept Reprod Health Care. 2020. PMID: 32069126 Clinical Trial.
-
Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial.Eur J Contracept Reprod Health Care. 2018 Oct;23(5):344-350. doi: 10.1080/13625187.2018.1531117. Epub 2018 Oct 29. Eur J Contracept Reprod Health Care. 2018. PMID: 30372645 Clinical Trial.
-
A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.Fertil Steril. 2016 Jul;106(1):151-157.e5. doi: 10.1016/j.fertnstert.2016.02.036. Epub 2016 Mar 24. Fertil Steril. 2016. PMID: 27016644 Clinical Trial.
-
Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea.Contraception. 2007 Jun;75(6 Suppl):S134-9. doi: 10.1016/j.contraception.2006.12.008. Epub 2007 Feb 16. Contraception. 2007. PMID: 17531605 Review.
-
The use of progestin subdermal implants in the management of endometriosis-related pain symptoms and quality of life: a systematic review.Curr Med Res Opin. 2022 Mar;38(3):479-486. doi: 10.1080/03007995.2022.2031144. Epub 2022 Feb 1. Curr Med Res Opin. 2022. PMID: 35048754
Cited by
-
In vivo effects of AZD4547, a novel fibroblast growth factor receptor inhibitor, in a mouse model of endometriosis.Pharmacol Res Perspect. 2021 Apr;9(2):e00759. doi: 10.1002/prp2.759. Pharmacol Res Perspect. 2021. PMID: 33811484 Free PMC article.
-
Levonorgestrel-releasing intrauterine system vs. systemic medication or blank control for women with dysmenorrhea: Systematic review and meta-analysis of randomized controlled trials.Front Glob Womens Health. 2022 Nov 2;3:1013921. doi: 10.3389/fgwh.2022.1013921. eCollection 2022. Front Glob Womens Health. 2022. PMID: 36405811 Free PMC article. Review.
-
The efficacy of progestins in managing pain associated with endometriosis, fibroids and pre-menstrual syndrome: a systematic review.Arch Gynecol Obstet. 2025 Jun;311(6):1511-1533. doi: 10.1007/s00404-025-07957-0. Epub 2025 Mar 11. Arch Gynecol Obstet. 2025. PMID: 40067480 Free PMC article.
-
Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery.Cochrane Database Syst Rev. 2021 Dec 20;12(12):CD005072. doi: 10.1002/14651858.CD005072.pub4. Cochrane Database Syst Rev. 2021. PMID: 34928503 Free PMC article.
-
Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety.BMC Womens Health. 2022 Dec 17;22(1):526. doi: 10.1186/s12905-022-02122-0. BMC Womens Health. 2022. PMID: 36528558 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical